CELLECTAR BIOSCIENCES INC

Cellectar Biosciences reported a reduced net loss of $5.7m for Q1 2026 (−13.6% year‑on‑year) and improved operational efficiency driven by lower R&D and G&A expenses. The company announced a $140m financing agreement intended to secure liquidity through Q2 2027. Positive clinical data from the CLOVER‑WaM phase IIb study in Waldenström’s macroglobulinemia were presented; the phase III trial for Iopofosin I‑131 is expected to start in late Q4 2026. The stock slipped slightly in pre‑market trading (−0.7%). » More on de.investing.com

Cellectar Biosciences has entered into securities purchase agreements for a registered direct offering and a private placement to raise up to $140 million, of which $35 million is available immediately and $105 million is in milestone‑linked securities. The transaction includes common stock, pre‑funded warrants and three tranche warrants with an exercise price of $2.65; executives are subscribing at $2.88. Nantahala Capital Management led the oversubscribed placement, and Andrew Gu is expected to join the board. The proceeds are intended to fund a confirmatory study and the submission of an NDA for iopofosin I 131 to treat Waldenström macroglobulinemia; a global study start is planned for Q4 2026. » More on de.investing.com

Cellectar announced an oversubscribed financing of up to $140 million, after which the stock rose 130% in premarket trading. The round is led by Nantahala Capital Management and includes immediate proceeds of about $35 million plus up to $105 million in milestone-based payments. Proceeds are intended to fund a confirmatory study and an NDA filing with the FDA for Iopofosin I 131 to treat Waldenström macroglobulinemia; a global confirmatory study is planned for Q4 2026. Upon closing, Andrew Gu of Nantahala will join the board of directors. » More on de.investing.com